StreetInsider.com News Articles

Form 4 Xeris Biopharma Holdings For: Mar 05 Filed by: Pieper Steven

Thu, 05 Mar 2026 19:18:00 -0500

si-local-file:///var/storage/secattach/20260305/26120917.html

Form 4 Xeris Biopharma Holdings For: Mar 05 Filed by: Pieper Steven

Thu, 05 Mar 2026 19:18:00 -0500

si-local-file:///var/storage/secattach/20260305/26120917.html

Form 4 Xeris Biopharma Holdings For: Mar 02 Filed by: Hecht Beth

Wed, 04 Mar 2026 17:29:00 -0500

si-local-file:///var/storage/secattach/20260304/26112856.html

Form 4 Xeris Biopharma Holdings For: Mar 02 Filed by: Hecht Beth

Wed, 04 Mar 2026 17:29:00 -0500

si-local-file:///var/storage/secattach/20260304/26112856.html

Form 144 Xeris Biopharma Holdings Filed by: Hecht Beth

Mon, 02 Mar 2026 16:36:00 -0500

si-local-file:///var/storage/secattach/20260302/26092961.html

Form 144 Xeris Biopharma Holdings Filed by: Hecht Beth

Mon, 02 Mar 2026 16:36:00 -0500

si-local-file:///var/storage/secattach/20260302/26092961.html

Form S-8 Xeris Biopharma Holdings

Mon, 02 Mar 2026 16:28:00 -0500

si-local-file:///var/storage/secattach/20260302/26092659.html

Form S-8 Xeris Biopharma Holdings

Mon, 02 Mar 2026 16:28:00 -0500

si-local-file:///var/storage/secattach/20260302/26092659.html

Form 10-K Xeris Biopharma Holdings For: Dec 31

Mon, 02 Mar 2026 16:26:00 -0500

si-local-file:///var/storage/secattach/20260302/26092631.html

Form 10-K Xeris Biopharma Holdings For: Dec 31

Mon, 02 Mar 2026 16:26:00 -0500

si-local-file:///var/storage/secattach/20260302/26092631.html

Form 8-K Xeris Biopharma Holdings For: Mar 02

Mon, 02 Mar 2026 07:08:00 -0500

si-local-file:///var/storage/secattach/20260302/26086874.html

Form 8-K Xeris Biopharma Holdings For: Mar 02

Mon, 02 Mar 2026 07:08:00 -0500

si-local-file:///var/storage/secattach/20260302/26086874.html

Xeris Pharmaceuticals Inc. (XERS) Tops Q4 EPS by 4c, provides guidance

Mon, 02 Mar 2026 07:03:30 -0500

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of $0.06, $0.04 better than the analyst estimate of $0.02. Revenue for the quarter came in at $85.81 million versus the consensus estimate of $81.38 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2026 revenue of $375-390 million, versus the consensus of $368 million.
Gross margin to improve modestly compared to 2025 reflecting favorable product mix.
R&D expense to increase by approximately $25 million compared to 2025 as the Company initiates its Phase 3 study for XP-8121.
SG&A expense to increase by approximately $45 million compared to 2025, driven primarily by investments in Recorlev.
Adjusted EBITDA1

Xeris Pharmaceuticals Inc. (XERS) Tops Q4 EPS by 4c, provides guidance

Mon, 02 Mar 2026 07:03:30 -0500

GUIDANCE:

Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

Mon, 02 Mar 2026 07:00:00 -0500

Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively

Provides full year 2026 total revenue guidance range of $375 million to $390 million

Hosts conference call and webcast today at 8:30 a.m. ET

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026.